Time of Treatment With LMWH in Cancer Patients With Thromboembolic Disease
Time of Treatment With Low Molecular Weight Heparins in Cancer Patients With Thromboembolic Disease. Procoagulant Role of Phospholipid-dependent Microparticles.
Cancer is the most important acquired risk factor of thromboembolisms. More than 20% of all episodes of venous thromboembolism (VT) or pulmonary thromboembolisms (PT) are cancer related. Cancer patients with VT or PT are treated with low molecular weight heparins (LMWH) during at least 3 months, but nowadays the duration of treatment is not accurately determined.
The D-Dimer determination has been used like recurrence predictors after LMWH treatment suspension, but in cancer patients the useful is limited. Phospholipid-dependent microparticles could been used like recurrence predictors in cancer patients and tailored the duration of LMWH treatment for each patient.
研究概览
详细说明
研究类型
注册 (实际的)
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
- Patient with diagnosis of cancer (any) and diagnosis of pulmonary thromboembolism (PT) or venous thromboembolism (VT) , in treatment with low molecular weight heparin (LMWH).
- Patients treated with LMWH since cancer diagnostic.
- Signed informed consent sheet
Exclusion Criteria:
- Patients with life expectancy lower than 6 months
- Pregnancy woman
- Patients with cerebral metastasis
学习计划
研究是如何设计的？
设计细节
- 观测模型：队列
- 时间观点：预期
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Recurrence thromboembolisms
大体时间：3 months
|
Venous thromboembolisms or Pulmonary thromboembolism recurrence after LMWH suppression
|
3 months
|
|
Recurrence thromboembolisms
大体时间：6 months
|
Venous thromboembolisms or Pulmonary thromboembolism recurrence after LMWH suppression
|
6 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Hemorrhagic events
大体时间：6 months
|
Hemorrhagic events due to LMWH treatment
|
6 months
|
|
Thromboembolic event attributable death
大体时间：6 months
|
Death related to embolic event
|
6 months
|
合作者和调查者
调查人员
- 学习椅：Remedios Otero Candelera, MD PhD、Hospital Universitario Virgen del Rocío IBIS
- 首席研究员：Teresa Elias, MD PhD、Hospitales Universitarios Virgen del Rocío
- 首席研究员：Isabel Blasco, MD、Hospital Universitario Virgen Macarena
- 首席研究员：Maria Rodriguez, MD、Hospital Universitario de Valme
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- Hispalis study
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)？
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.